RT Journal Article
T1 Liposomes as vehicles for topical ophthalmic drug delivery and ocular surface protection
A1 López Cano, José Javier
A1 González-Cela Casamayor, Miriam Ana
A1 Andrés Guerrero, Vanesa
A1 Herrero Vanrell, María Del Rocío
A1 Molina Martínez, Irene Teresa
AB Introduction: The development of ophthalmic formulations able to deliver hydrophilic and hydrophobic drugs to the inner structures of the eye and restore the preocular tear film has been a leading topic of discussion over the last few years. In this sense, liposomes represent a suitable strategy to achieve these objectives in ocular drug delivery.Areas covered: Knowledge of the different physiological and anatomical eye structures, and specially the ocular surface are critical to better understanding and comprehending the characteristics required for the development of topical ophthalmic liposomal formulations. In this review, several features of liposomes are discussed such as the main materials used for their fabrication, basic structure and preparation methods, from already established to novel techniques, allowing the control and design of special characteristics. Besides, physicochemical properties, purification processes and strategies to overcome delivery or encapsulation challenges are also presented.Expert opinion: Regarding ocular drug delivery of liposomes, there are some features that can be redesigned. Specific biocompatible and biodegradable materials presenting therapeutic properties, such as lipidic compounds or polymers significantly change the way of tackling ophthalmic diseases.Besides, liposomes entail an effective, safe and versatile strategy for the treatment of diseases in the clinical practice.
PB Taylor & Francis
SN 1744-7593
YR 2021
FD 2021-01-22
LK https://hdl.handle.net/20.500.14352/7810
UL https://hdl.handle.net/20.500.14352/7810
LA eng
NO López Cano, J. J., González-Cela Casamayor, M. M., Andrés Guerrero, V. et al. «Liposomes as Vehicles for Topical Ophthalmic Drug Delivery and Ocular Surface Protection». Expert Opinion on Drug Delivery, vol. 18, n.o 7, julio de 2021, pp. 819-47. DOI.org (Crossref), https://doi.org/10.1080/17425247.2021.1872542.
NO Funding: Research Group UCM 920415, Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal), ISCIII-FEDER RETICS (OFTARED) (RD16/0008/0009 and RD16/0008/0004), FEDER-CICYT FIS-PI17/00079 and PI17/00466
NO Instituto de Salud Carlos III
NO Fondo Europeo de Desarrollo Regional
NO Redes temáticas de Investigación Cooperativa en Salud
NO Ministerio de Economía, Comercio y Empresa (España)/Fondo Europeo de Desarrollo Regional
NO Universidad Complutense de Madrid
DS Docta Complutense
RD 17 abr 2025